[The PM-Scl (polymyositis-scleroderma) autoantibody and its nucleolar fluorescence pattern]

Area of Science:

• Immunology
• Rheumatology
• Cell Biology

Background:

• Antinuclear antibodies (ANAs) are crucial biomarkers in diagnosing connective tissue diseases (CTDs).
• Specific ANA staining patterns can indicate particular autoantibodies and associated clinical manifestations.
• Distinguishing between different nucleolar and nucleoplasmic staining patterns is essential for accurate diagnosis.

Purpose of the Study:

• To determine the nuclear staining pattern of antinuclear antibodies in patients with connective tissue diseases.
• To associate specific staining patterns with antibody specificities and clinical diagnoses.
• To differentiate the PM-Scl antibody staining pattern from other relevant patterns like Scl-70.

Main Methods:

• Indirect immunofluorescence studies using hamster liver imprints as a substrate.
• Analysis of antinuclear antibody staining patterns (nucleolar, nucleoplasmic).
• Immunodiffusion assays to confirm antibody specificity (PM-Scl).

Main Results:

• Ten sera exhibited a distinct homogeneous nucleolar staining pattern, with associated weaker speckled or homogeneous nucleoplasmic fluorescence.
• In all ten cases, antibodies confirmed PM-Scl specificity via immunodiffusion.
• Clinically, nine patients had acrosclerosis, with 56% overlapping with polymyositis symptoms; one had diffuse scleroderma.

Conclusions:

• The homogeneous nucleolar immunofluorescence pattern is characteristic of PM-Scl antibodies.
• This pattern should be distinguished from the mixed nucleolar and diffuse reticular nucleoplasmic pattern associated with Scl-70 antibodies.
• PM-Scl antibodies are frequently observed in patients with acrosclerosis and polymyositis overlap symptoms.